CAR-T cells bispecifically targeting CD13 and TIM3, which are upregulated in LSCs, eliminated patient-derived AML while reducing the cytotoxicity of stem cells and peripheral myeloid cells in mouse models. Here, HAVCR2 is linked to acute myeloid leukemia.